Business
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
Initial data reports one of the most critical signaling pathways for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Initial data reports one of the most critical signaling pathways for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003\n\n\nNEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin. \n\n \n \n \n \n \n \n\n \nDr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, is lead on the study. \"Thanks to Dr. Zippin and his team, we have gained significant insight for the therapeutic potential of HT-003 for the treatment of acne,\" stated Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics\nToll-like receptor 2 (TLR2) is one of the most critical pathways for acne pathophysiology. The data generated from this series of in vitro experiments shows that TLR2 is significantly inhibited by HT-003, including in the presence of TLR2 agonists. Baseline expression of TLR2 and a critical transcription factor for skin inflammation (NF-KB) are inhibited by HT-003. \n\"The ability of HT-003 to potently inhibit TLR2 signaling pathway suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by overactive inflammatory responses to bacteria,\" stated Dr. Zippin. \nDr. Zippin will continue to investigate the therapeutic mechanism of action of HT-003 through in vitro dose-response analyses and in animal models. \nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.\nForward-Looking StatementThis press release includes forward-looking statements based upon Hoth's current e...